Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

Tzouvelekis, 2012, Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions, Clin Microbiol Rev, 25, 682, 10.1128/CMR.05035-11 Falagas, 2014, Deaths attributable to carbapenem-resistant Enterobacteriaceae infections, Emerg Infect Dis, 20, 1170, 10.3201/eid2007.121004 Fraenkel-Wandel, 2016, Mortality due to blaKPC Klebsiella pneumoniae bacteraemia, J Antimicrob Chemother, 71, 1083, 10.1093/jac/dkv414 Tumbarello, 2012, Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy, Clin Infect Dis, 55, 943, 10.1093/cid/cis588 Qureshi, 2012, Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens, Antimicrob Agents Chemother, 56, 2108, 10.1128/AAC.06268-11 Daikos, 2014, Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems, Antimicrob Agents Chemother, 58, 2322, 10.1128/AAC.02166-13 Palacios-Baena, 2016, Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain, J Infect, 72, 152, 10.1016/j.jinf.2015.10.008 Lee, 2016, Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods, Front Microbiol, 7, 895, 10.3389/fmicb.2016.00895 Paul, 2014, Combination therapy for carbapenem-resistant Gram-negative bacteria, J Antimicrob Chemother, 69, 2305, 10.1093/jac/dku168 Gomez-Simmonds, 2016, Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections, Antimicrob Agents Chemother, 60, 3601, 10.1128/AAC.03007-15 Rodríguez-Baño, 2015, Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology, Enferm Infecc Microbiol Clin, 33, 337.e1, 10.1016/j.eimc.2014.11.009 Gutiérrez-Gutiérrez, 2016, A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae, Mayo Clin Proc, 91, 1362, 10.1016/j.mayocp.2016.06.024 Charlson, 1987, A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation, J Chron Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Hilf, 1989, Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients, Am J Med, 87, 540, 10.1016/S0002-9343(89)80611-4 Levy, 2003, 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference, Crit Care Med, 31, 1250, 10.1097/01.CCM.0000050454.01978.3B 2012 Tumbarello, 2015, Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study, J Antimicrob Chemother, 70, 2133, 10.1093/jac/dkv086 Daikos, 2011, Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?, Clin Microbiol Infect, 17, 1135, 10.1111/j.1469-0691.2011.03553.x Viale, 2013, Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections, Expert Rev Anti Infect Ther, 11, 1053, 10.1586/14787210.2013.836057 Zarkotou, 2011, Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment, Clin Microbiol Infect, 17, 1798, 10.1111/j.1469-0691.2011.03514.x Falcone, 2016, Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae, Clin Microbiol Infect, 22, 444, 10.1016/j.cmi.2016.01.016 Dickstein, 2016, Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol, BMJ Open, 6, e009956, 10.1136/bmjopen-2015-009956